Live talk, session 10 – June 30, 2022: emotional well-being, mental health and the pituitary

July 1, 2022

Mental health and emotional wellness are essential topics for pituitary patients, their families, and friends. This on-demand session from last Thursday’s live-talk program focuses on the challenges and opportunities when considering these issues. This is a compelling discussion from the psychological and the medical point of view about the importance of putting people’s mental and emotional well-being center stage when considering the medical and psychological treatment of endocrine disorders. PWN contributor and author Linda M Rio chats with Dr. Lewis Blevis and myself about tools and resources and the need for more research and work in this critical pituitary patient care and wellness area.

Mifepristone (Korlym®)

December 9, 2021

In the last podcast in the series on the drugs available to manage hypercortisolism, Dr. Blevins discusses mifepristone, trade name Korlym®.

Isturisa® (osilodrostat)

December 6, 2021

Our third podcast in the series is on osilodrostat (trade name Isturisa®), a drug approved by the FDA in the US and the European Medicines Agency (EMA) to treat hypercortisolism in patients who are not candidates for surgery or those that surgery did not work.  In this podcast, Dr. BLevins takes us inside his clinical practice to share his experiences with the drug.

Metyrapone

December 3, 2021

The second podcast in our series on the medical management of hypercortisolism focuses on the drug metyrapone. Dr. Blevins discusses the drug uses, how it works, and its side effects. 

Coming up next, a discussion on the drug Isturiza® (osilodrostat).

Ketoconazole

December 2, 2021

This is the first in our series of five podcasts on the medical management of Hypercortisolism due to Cushing’s disease. Today Dr. Blevins discusses the drug Ketoconazole. Tune in tomorrow to listen to the second podcast in the series on the use of Metyrapone, and on Monday, don’t miss the podcast on Isturisa® (osilodrostat).

The challenges and opportunities in new hypercortisolism drugs

November 17, 2021

Today we welcome three renowned experts in the development of drugs to treat hypercortisolism. Dr. Blevins and I discuss their research, clinical trials, challenges, and opportunities for these essential medications that could immensely affect patient well-being and quality of life. This discussion touches on the fascinating details of hypercortisolism and the developments now and in the future.

Acromegaly: the last 30 years

October 29, 2021

In this Podcast, Dr. Blevins gives us a perspective of the last 30 years on the developments in this field. Like many other conditions, the advances in therapy, imaging, surgery techniques, diagnostic testing, and clinical knowledge have been nothing short of remarkable.